IPRATROPIUM BROMIDE

First approved in 1986

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H30NO3.Br.H2O
Molecular Weight	430.376
Optical Activity	( + / - )
Defined Stereocenters	4 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[Br-].CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)C3=CC=CC=C3

InChI

InChIKey=KEWHKYJURDBRMN-KMYPTGJZSA-M

InChI=1S/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1/t16-,17+,18+,19-,21?;;/m0../s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68009241

Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Ipratropium (ipratropium bromide, ATROVENT® HFA) is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca2+ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 169 Target ID: CHEMBL216 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2778	0.49 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2778	1.5 nM [Ki]
Muscarinic acetylcholine receptor M3 159 Target ID: CHEMBL245 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2778	0.51 nM [Ki]
Muscarinic acetylcholine receptor M4 86 Target ID: CHEMBL1821 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2778	0.66 nM [Ki]
Muscarinic acetylcholine receptor M5 62 Target ID: CHEMBL2035 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2778	1.7 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic obstructive pulmonary disease 174 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Primary		Approved 8429	ATROVENT HFA Approved Use ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
33.5 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
31.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN
35.4 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1.04 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN
131 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
95.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	Disc. AE: Nasal disorder NOS, Nasal dryness... AEs leading to discontinuation/dose reduction: Nasal disorder NOS (17%) Nasal dryness (2%) Epistaxis (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 43 Health Status: unhealthy Condition: common colds Age Group: 2 - 5 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	Disc. AE: Epistaxis... AEs leading to discontinuation/dose reduction: Epistaxis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	Disc. AE: Epistaxis, Upper respiratory tract infection... AEs leading to discontinuation/dose reduction: Epistaxis (1 patient) Upper respiratory tract infection (1 patient) Ear infection (1 patient) Exacerbation of asthma (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
200 ug single, respiratory Highest studied dose Dose: 200 ug Route: respiratory Route: single Dose: 200 ug Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/	unhealthy, mean 40.7 years n = 20 Health Status: unhealthy Condition: stable chronic asthma Age Group: mean 40.7 years Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/	Disc. AE: Nausea and vomiting... AEs leading to discontinuation/dose reduction: Nausea and vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/
42 ug 1 times / day steady, respiratory Recommended Dose: 42 ug, 1 times / day Route: respiratory Route: steady Dose: 42 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/	unhealthy, mean 42.6 years n = 99 Health Status: unhealthy Condition: rhinorrhea Age Group: mean 42.6 years Sex: M+F Population Size: 99 Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/	Other AEs: Nasal disorder NOS... Other AEs: Nasal disorder NOS (19 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/

AEs

AE	Significance	Dose	Population
Nasal disorder NOS	17% Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
Epistaxis	2% Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
Nasal dryness	2% Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years n = 96 Health Status: unhealthy Condition: perennial allergic rhinitis Age Group: 18 - 75 years Sex: M+F Population Size: 96 Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
Epistaxis	1 patient Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 43 Health Status: unhealthy Condition: common colds Age Group: 2 - 5 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Ear infection	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Epistaxis	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Exacerbation of asthma	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Upper respiratory tract infection	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years n = 187 Health Status: unhealthy Condition: allergies Age Group: 2 - 5 years Sex: M+F Population Size: 187 Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Nausea and vomiting	1 patient Disc. AE	200 ug single, respiratory Highest studied dose Dose: 200 ug Route: respiratory Route: single Dose: 200 ug Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/	unhealthy, mean 40.7 years n = 20 Health Status: unhealthy Condition: stable chronic asthma Age Group: mean 40.7 years Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/
Nasal disorder NOS	19 patients	42 ug 1 times / day steady, respiratory Recommended Dose: 42 ug, 1 times / day Route: respiratory Route: steady Dose: 42 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/	unhealthy, mean 42.6 years n = 99 Health Status: unhealthy Condition: rhinorrhea Age Group: mean 42.6 years Sex: M+F Population Size: 99 Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 512 OCT2 647 OCT3 150 MATE1 306 MATE2 263	OCTN1 47 OCTN2 50 OCT1 327 OCT2 355 OCT3 80 MATE1 135 MATE2 96

Drug as perpetrator

Target	Modality	Activity
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 17.4 uM]
OCT3 150	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 2.5 uM]
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 3.6 uM]
MATE1 308	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 30.5 uM]
MATE2 263	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 62.8 uM]

Drug as victim

Target	Modality	Activity
MATE1 135	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
MATE2 96	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCT2 355	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCT3 80	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCTN1 47	substrate 3367 Sources: https://pubs.acs.org/doi/10.1021/mp900206j	yes
OCTN2 50	substrate 3367 Sources: https://pubs.acs.org/doi/10.1021/mp900206j	yes

Sourcing

Vendor/Aggregator	ID	URL
KeyOrganics	KS-5051
Pharmeks	PHAR218016
ZINC	ZINC000013782937	http://zinc15.docking.org/substances/ZINC000013782937

PubMed

Title	Date	PubMed
Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.	2001	11735662
Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children.	2001 Dec	11737740
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.	2001 Dec	11732951
Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease.	2001 Jan	11779443
Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog.	2001 Jul	11745922
Does adding ipratropium to salbutamol (albuterol) help children with asthma?	2001 Nov	12035817
Lower arrythmogenic risk of low dose albuterol plus ipratropium.	2001 Oct	11758131
Drug therapy of childhood asthma.	2001 Sep	11980463
[Effect of anticholinergic therapy on myocardial reserve dynamics in patients with chronic obstructive bronchitis].	2001 Sep-Dec	11881364
Cold-induced rhinitis in skiers--clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial.	2001 Sep-Oct	11732814
[Asthma follow-up after treatment of status asthmaticus in ICU Pneumonology Department in Warsaw Medical University].	2002	12148180
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.	2002	12119057
Role of cholinergic reflexes on the bronchoconstrictor reactivity to neurokinin a in allergic dogs.	2002	12090791
Heliox for treatment of exacerbations of chronic obstructive pulmonary disease.	2002	12076487
Histochemical and biochemical studies on the secretory mechanisms of some glands of guinea-pigs treated with histamine.	2002	12056651
Tiotropium bromide.	2002	12010082
[Pharmacodynamics of inhalation broncholytic agents introduced in a single dose by nebulizer in patients with severe exacerbation of bronchial asthma].	2002	11980113
Management of children with severe asthma exacerbation in the emergency department.	2002	11909006
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.	2002	11869627
Anticholinergic drugs for wheeze in children under the age of two years.	2002	11869598
Pharmacogenetics, pharmacogenomics and airway disease.	2002	11806845
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.	2002 Apr	11998992
Do bronchodilators have an effect on bronchiolitis?	2002 Apr	11983033
Differential response of wheezes and ruttles to anticholinergics.	2002 Apr	11919106
Intravenous versus oral corticosteroids for treatment of acute asthma exacerbations.	2002 Apr	11918500
Airways reactivity in patients with CF.	2002 Aug	12162108
Hospitalizations and mortality in the Lung Health Study.	2002 Aug 1	12153966
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].	2002 Aug 5	12162793
Clinical review: severe asthma.	2002 Feb	11940264
[Benefits of ipratropium bromide in the management of asthmatic crises in the emergency department].	2002 Feb	11915491
Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department.	2002 Feb	11889328
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.	2002 Feb	11871363
Other option in bronchiolitis.	2002 Feb	11867862
Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice.	2002 Feb	11819029
Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.	2002 Feb	11812272
Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen.	2002 Feb	11812271
Effects of inhaled ipratropium bromide on breathing mechanics and gas exchange in exercising horses with chronic obstructive pulmonary disease.	2002 Jan	11817550
The incremental shuttle walking test in elderly people with chronic airflow limitation.	2002 Jan	11809987
Emergency department asthma: compliance with an evidence-based management algorithm.	2002 Jul	12161875
Management of acute, severe asthma in children.	2002 Jul-Aug	12086560
Hospital management of children with acute asthma exacerbations in Kuwait: adherence to international guidelines.	2002 Jul-Sep	12138293
Treatment and quality of life in patients with chronic obstructive pulmonary disease.	2002 Jun	12086118
The role of anticholinergics in acute asthma treatment: an evidence-based evaluation.	2002 Jun	12065366
Understanding and use of inhaler medication by asthmatics in specialty care in Trinidad: a study following development of Caribbean guidelines for asthma management and prevention.	2002 Jun	12065346
Mydriasis due to self-administered inhaled ipratropium bromide.	2002 Mar	11998922
In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome?	2002 Mar	11978242
Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD.	2002 Mar	11888949
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.	2002 Mar 1	11874817
[Effect of ipratropium bromide on calcium activated potassium channel in tracheal smooth muscle cells from chronically hypoxic rats].	2002 May	12133322
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?	2002 May	12030735

Patents

Sample Use Guides

In Vivo Use Guide

The usual starting dose of ATROVENT® HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours.

Route of Administration: Oral

In Vitro Use Guide

Ba 679 BR, atropine, and ipratropium bromide inhibited electrical field stimulation (EFS)-induced contraction with IC50 values of 0.17, 0.74, and 0.58 nM, respectively, in guinea pig trachea. Ba 679 BR had a slower onset and longer duration of action than atropine or ipratropium bromide (the times required to attain 50% of the maximum response were 34.8, 3.8, and 7.6 min, respectively, and the times required for 50% recovery of the response were 540, 31.6, and 81.2 min, respectively).

Name

Type

Language

IPRATROPIUM BROMIDE

Official Name

English

IPRATROPIUM BROMIDE COMPONENT OF DUOVENT

Brand Name

English

COMBIVENT COMPONENT IPRATROPIUM BROMIDE

Common Name

English

IPRATROPIUM BROMIDE [VANDF]

Common Name

English

IPRATROPIUM BROMIDE [USP MONOGRAPH]

Common Name

English

IPRATROPIUM BROMIDE [USP-RS]

Common Name

English

DUONEB COMPONENT IPRATROPIUM BROMIDE

Common Name

English

IPRATROPIUM BROMIDE HYDRATE [JAN]

Common Name

English

DUOVENT COMPONENT IPRATROPIUM BROMIDE

Brand Name

English

SCH 1000-BR-MONOHYDRATE

Code

English

IPRATROPIUM BROMIDE COMPONENT OF COMBIVENT

Common Name

English

IPRATROPIUM BROMIDE COMPONENT OF DUONEB

Common Name

English

8-AZONIABICYCLO(3.2.1)OCTANE, 3-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-8-METHYL-8-(1-METHYLETHYL)-, BROMIDE, MONOHYDRATE(ENDO,SYN)-, (±)-

Common Name

English

IPRATROPIUM BROMIDE [ORANGE BOOK]

Common Name

English

NSC-759613

Code

English

IPRATROPIUM BROMIDE [MART.]

Common Name

English

IPRATROPIUM BROMIDE HYDRATE

Common Name

English

(8R)-3.ALPHA.-HYDROXY-8-ISOPROPYL-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE (±)-TROPATE MONOHYDRATE

Common Name

English

SCH-1000-BR-

Code

English

ATROVENT

Brand Name

English

Ipratropium bromide monohydrate [WHO-DD]

Common Name

English

IPRATROPIUM BROMIDE [USAN]

Common Name

English

IPRATROPIUM BROMIDE [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR01AX03